Date: 21 st May 2014 Version: 5 Page 1 of 11. Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May 2014
|
|
- Miles McKinney
- 6 years ago
- Views:
Transcription
1 Date: 21 st May 2014 Version: 5 Page 1 of 11 STANDARD OPERATING PROCEDURE FOR MONITORING CLINICAL TRIALS (NWORTH 3.07) Approvals Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May 2014 Quality Assurance Officer Name: p.p. J. Ryan Signature: J. Ryan Date: 22 nd May 2014 NWORTH Director Name: R.T. Woods Signature: R.T. Woods Date: 27 th May 2014 Disclaimer: Printed SOP's are considered uncontrolled. To ensure you are working with current version always refer to the pdf version on the NWORTH website North Wales Organisation for Randomised Trials in Health (& Social Care) (NWORTH) Institute of Medical & Social Care Research (IMSCaR) Y Wern, Holyhead Road, Bangor University, Bangor, Gwynedd, LL57 2PZ Telephone: nworth@bangor.ac.uk
2 SOP number: NWORTH 3.07 Page 2 of 11 DOCUMENT HISTORY Version number Effective date Authorship (compiled) S.H. Roberts S.H. Roberts E. Bedson S.H. Roberts E. Bedson 4 29/03/12 S.H. Roberts E. Bedson D. Skelhorn Summary of changes New Updates SOP numbering and layout, safety monitoring reported in SOP 4.03 Responsibilities updated and minor text changes to section5 5 02/06/14 D. Skelhorn Minor changes. Layout and SOP references standardised, links updated, reference to monitoring plan development added to flowchart and section 5.3, duplication removed from section Table of Contents 1. Table of Contents Purpose Scope Responsibilities Procedure Process Flow chart Overview of monitoring requirements Setting up a trial monitoring structure Safety monitoring and reporting Inspections and site visits Training plan for SOP implementation Glossary of Terms References Referenced SOPs Appendices... 11
3 SOP number: NWORTH 3.07 Page 3 of Purpose To describe the way trial monitoring will be planned and carried out by NWORTH. 3. Scope This SOP applies only to trials where all monitoring responsibilities have been delegated to NWORTH. For the purposes of this SOP, the term monitor will be used to refer to any member or committee designated by NWORTH to undertake specific monitoring task. 4. Responsibilities All staff associated with NWORTH who have been delegated monitoring activities should ensure that they are familiar with this SOP, particularly staff working in clinical trials with Investigational Medicinal Products (IMPs). The sponsor has overall responsibility for ensuring a trial is monitored (see SOP 4.04 arranging sponsorship, contracts/agreements and indemnity). However, the sponsor can delegate trial monitoring activities to NWORTH. Where the University is the sponsor, monitoring activities may be delegated to NWORTH through the CoHaBS board. NWORTH Trials Unit Manager is responsible for ensuring: that the requirements of this SOP are adhered to, the tasks that are delegated to the trial manager are clearly documented in the delegation log. Trial Manager (TM) - when delegated monitoring duties is responsible for ensuring they have: a thorough understanding of trial monitoring requirement as documented in the Research Governance Framework for Health and Social Care and for good clinical practice guidelines (where applicable ICH topic E6(R1)), a thorough understanding of the relevant clinical trials (CT) regulations, adequate documented training to carry out the monitoring activities, when tasks specified within this SOP are delegated to the TM.
4 SOP number: NWORTH 3.07 Page 4 of Procedure 5.1 Process Flow chart Sponsor in discussion with NWORTH determines level of monitoring required Develop monitoring plan during protocol development, based on risk assessment Trial Manager or other person/committee appointed to carry out monitoring duties Is a monitoring committee required? Yes Monitoring structure established (Sponsor may delegate the task of setting up TMG, TSC, and DMEC to NWORTH, CI / PI, or TM). No Verification that conduct of trial is in accordance with the protocol and principles of GCP Report findings to CI/PI and Sponsor Note: Safety monitoring and reporting is NWORTH 4.03 Safety monitoring including pharmacovigilance.
5 SOP number: NWORTH 3.07 Page 5 of Overview of monitoring requirements Monitoring is defined in section 1.38 of the ICH guideline GCP as: The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP) and the applicable regulatory requirement(s) According to section of the ICH guideline GCP, the purposes of trial monitoring are to verify that the: Rights and well-being of the human participants are protected Reported trial data are accurate, complete and verifiable from source documents; Conduct of the trial is in compliance with the currently approved protocol / amendment(s), with GCP and with the applicable regulatory requirements. Note: Adherence to GCP is required for all clinical trials. However, adherence to ICH guideline (E6(R1)) is required only for commercial CTIMP studies but provides a good example how monitoring activities should be set up and implemented for other trials. Setting up a trial monitoring structure and reporting Adverse Events (AEs) are key monitoring activities. This SOP will provide guidance on setting up the monitoring structure only. For AE reporting see SOP 4.03 Safety monitoring including Pharmacovigilance. For CTIMPs a formal monitoring structure must be established where the role and responsibilities of the monitor(s) are delegated to the Trial Steering Committee (TSC). This is also true for CTs of non-pharmacological interventions. The duties associated with monitoring can then be delegated to NWORTH by the TSC. Central monitoring of data using statistical techniques is also useful for identifying unusual patterns in the data and can be used to identify sites or contributors that may be deviating from the protocol. In line with GCP, individuals monitoring trials should be appropriately trained and have the scientific/clinical knowledge needed to monitor the trial adequately. A formal record of the qualifications and training of monitoring individuals should be kept. They should be thoroughly familiar with the intervention, the protocol, consent form and any other written information to be provided to human participants, the sponsor s SOPs relating to clinical trials, relevant NWORTH SOPs, GCP and the applicable regulatory requirement(s). The monitor(s) should act as the main line of communication between the sponsor and the investigator(s), and their responsibilities include: verifying that the investigator has adequate qualifications and resources, and will remain adequate throughout the trial period; and that facilities including laboratories, equipment, and staff, are adequate to safely and properly conduct the trial verifying that storage conditions, supplies, instructions, dispensing recording and disposal of the investigational product(s) are acceptable
6 SOP number: NWORTH 3.07 Page 6 of 11 Verifying, for investigational product(s): a) that the investigational product(s) are supplied only to subjects who are eligible to receive it and at the protocol specified dose(s) b) subjects are provided with necessary instruction on properly using, handling, storing and returning the investigational product(s). c) the receipt, use, and return of the investigational product(s) at the trial sites are controlled and documented adequately d) the disposition of unused investigational product(s) at the trial sites complies with applicable regulatory requirement(s) and is in accordance with the sponsor. verifying that investigator(s) comply with the protocol verifying that written consent is obtained for each participant verifying that investigator(s) have all the up-to-date required documents to conduct the trial properly and to comply with the regulatory bodies ensuring that all investigator(s) and trial staff are adequately informed of the trial verifying that all investigator(s) and trial staff are adequately performing the trial functions in accordance with the protocol and any agreement with the sponsor, and have not delegated these functions to unauthorised individuals verifying that investigator(s) are enrolling only eligible subjects reporting subject recruitment rates verifying that source documents and other trial records are accurate, complete, kept up-to-date and maintained checking completeness of CRFs by specifically verifying that: a. the data required by the protocol are reported accurately on the CRF b. treatment modifications are well documented for each trial subject c. AEs are reported in accordance to the protocol d. visits or tests/examinations which were not conducted are clearly reported as such on the CRF e. all withdrawals and dropouts are reported and explained on the CRF and investigator(s) informed of any error on the CRF determining whether all AEs are reported adequately in the time frames specified by the protocol, sponsor, and regulatory authorities determining whether essential documents in the Trial Master File (TMF) are maintained communicating deviations from the protocol, SOPs, GCP, and the applicable regulatory requirements to the investigator and taking appropriate action designed to prevent recurrence of the detected deviations Monitoring is designed to demonstrate a trial s quality by continuously verifying that trial related activities are performed appropriately and to quality standards, i.e. in line with current protocol, GCP and regulatory requirements (Quality Control (QC)). Assessing and assuring the reliability and integrity of the quality control systems is undertaken through audit rather than by monitoring as this type of Quality Assurance (QA) is about measuring performance against a set of standards. Implementing QA is also the responsibility of the sponsor but is not covered by this SOP. This SOP is concerned only with monitoring (i.e. QC).
7 SOP number: NWORTH 3.07 Page 7 of 11 Prior to a trial starting, the sponsor in discussion with the CI/PI (and where applicable NWORTH) will decide the extent and nature of monitoring required. The type of monitoring should reflect the size, complexity and risks (both to the human participants and to the results) associated with the trial. Specific trial monitoring procedures and processes should be detailed in the trial protocol (see SOP 3.02 Protocol Development). 5.3 Setting up a trial monitoring structure An appropriate trial monitoring structure must be in place for all trials. For some trials (e.g. pilot studies or non-drug trials) the sponsor may deem it acceptable to identify an appropriately trained person to serve as monitor. Where possible the monitoring plan should be developed during protocol development and should be based on a risk assessment of the study.the Sponsor and the CI need to agree the monitoring plan and determine the extent and nature of monitoring required as stated above. For large, multi-centre trials and/or CTIMPs, an independent monitoring structure is required. This structure should be as follows: Trial Management Group (TMG) Individuals responsible for the day-to-day running of the trial should be included in this group. These include CI, PIs, TM, statistician, research staff, data manager, and collaborating clinicians, as necessary. The TMG s role is to monitor all aspects of the trial s conduct and progress. The group should ensure the protocol is adhered to, take appropriate action to safeguard participants, and ensure the quality of the trial itself. Trial Steering Committee (TSC) A TSC is set up to oversee the running of the trial on behalf of the sponsor/funder and has the overall responsibility for the continuation or termination of the trial. Committee membership should include individuals who are independent of the trial and investigators (in particular an independent chairperson), a public involvement representative as well as the CI and TM. The role of the TSC is to ensure that the trial is being conducted in accordance with the principles of GCP and the relevant regulations, and provide advice on all aspects of the trial. A trial protocol and any subsequent amendments must be agreed by the TSC. Data Monitoring and Ethics Committee (DMEC) It is NWORTH policy that an independent DMEC should be set up for all full trials and must be set up for any trial of an investigational medicinal product (IMP) or medical device (MD). The DMEC may be a subcommittee of the TSC providing all members are independent from the trial investigators and sponsor/funder, and that a sufficient quorum of the remaining independent TSC members (no less than 2 members) is available for decision making. The role of the DMEC is to review the accruing trial data and to assess whether there are any concerns about the safety of the intervention. DMECs are responsible for considering any newly published research data which might affect the trial, any additional information that should be passed on to participants, and any reasons that affect the continuation of the trial. The trial
8 SOP number: NWORTH 3.07 Page 8 of 11 statistician must be available to answer any questions and to provide blinded and, if requested, unblinded trial data for interim analysis. The TMG will provide regular safety reports to the DMEC. The DMEC reports to and makes recommendations to the TSC. Day to day monitoring of the trial must take place to ensure that: collected data are consistent with protocol adherence; only authorised persons complete Case Report Forms (CRFs); there are no missing data; data are valid through validation checks (e.g. range and consistency checks); and, recruitment rates, withdrawals and losses to follow-up are reviewed overall and by site. Communication is key to the effective monitoring of a trial. The CI/PI will communicate regularly with: staff involved with conducting the trial; all PIs at participating sites; and the clinical trials unit NWORTH. It is considered good practice for the Sponsor to provide an annual progress report to the REC, The HRA web site contains a standard template for reporting. 5.4 Safety monitoring and reporting For monitoring and reporting the safety of an intervention see NWORTH SOP 4.03 Safety monitoring including Pharmacovigilance which covers the requirements for MHRA Development update safety reports (DSURs). 5.5 Inspections and site visits As part of the monitoring process, on-site visits may be necessary to verify the appropriate conduct of the trial, particularly for multi-centre trials. In general there is a need for on-site monitoring, before, during, and after the trial. Arrangements for site visiting may vary from routine visits to all sites, visits to a random selection of sites or visits targeted at less experienced sites or those for which the trial s central monitoring procedures suggested possible problems. For trials involving an investigational medical product or a medical device, the MHRA may make additional site visits to ensure compliance with the regulations (see NWORTH SOP 4.02 for MHRA approval). Following each site visit the monitor or monitoring committee should submit a written report to the CI with a copy to the PI and site staff. The report should include: the date, site, name of the monitor(s) and name of the investigator or other individual(s) contacted a summary of what the monitor(s) reviewed and the monitors statements concerning the significant findings, deviations and deficiencies, conclusions, actions taken or to be taken and/or actions recommended to secure compliance
9 SOP number: NWORTH 3.07 Page 9 of 11 The review and follow-up of the monitoring reports on the site visits should be documented by the CI (or person to whom the CI has delegated this duty). 6. Training plan for SOP implementation Training will be carried out in accordance with NWORTH training SOP Glossary of Terms AE Adverse Event Any adverse occurrence happening to a patient in a clinical trial, whether or not that occurrence is thought to be a reaction to the trial intervention. An AE can be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the trial intervention. CI Chief Investigator The investigator with overall responsibility for the research. In a multi-site study, the CI has co-ordinating responsibility for research at all sites. All applications for ethical review should be submitted by the CI. CRF Case Report Form A printed, optical or electronic document designed to record all of the protocolrequired information to be reported to the sponsor on each trial subject. CTIMP Clinical Trial of an Investigational Medicinal Product Any investigation in human subjects, other than a non-interventional trial, intended: a. To discover or verify the clinical, pharmacodynamic effects of one or more medicinal products; b. To identify any adverse reactions to one or more such products; c. To study absorption, distribution, metabolism and excretion of one or more such products with object of ascertaining the safety or efficacy of those products. DMEC GCP Data Monitoring and Ethics Committee Good Clinical Practice, as defined by the ICH ICH International Conference on Harmonisation of Technical Requirementsof registration of pharmaceuticals for human use. IMP Investigational Medicinal Product A pharmaceutical form of an active substance or placebo being tested, or used, or to be used, as a reference in a clinical trial, and includes a medicinal product which has a marketing authorisation but is, for the purposes of the trial: a. Used or assembled (formulated or packaged) in a way different from the form of the product authorised under the authorisation; b. Used for an indication not included in the summary of product characteristics under the authorisation for that product;
10 SOP number: NWORTH 3.07 Page 10 of 11 c. Use to gain further information about the form of that product which are relevant to the study of the product in human subjects. MD Medical Device Any instrument, apparatus, appliance, material or other article, whether used alone or in combination, including the software necessary for its proper application intended by the manufacturer to be used for human beings for the purpose of: - diagnosis, prevention, monitoring, treatment or alleviation of disease, - diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap, - investigation, replacement or modification of the anatomy or of a physiological process, - control of conception, and which does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its function by such means. MHRA Medicines and Healthcare products Regulatory Agency MHRA (medicines) is the competent authority for the UK in relation to the EU Directive and the Clinical Trials Regulations. MHRA (Devices) is the competent authority for the UK in relation to the medical Devices Regulations NWORTH care) North Wales Organisation for Randomised Trials in Health (and social PI Principal Investigator The investigator responsible for the research site where the study involves specific procedures requiring site-specific assessment. There should be one PI for each research site. In the case of a single-site study, the CI and PI will normally be the same person. QA Quality Assurance All those planned and systematic actions that are established to ensure that the trial is performed and the data are generated, documented (recorded), and reported in compliance with Good Clinical Practice (GCP) and the applicable regulatory requirement(s). QC Quality Control The operational techniques and activities undertaken within the quality assurance system to verify that the requirements for quality of the trial-related activities have been fulfilled. Sponsor The person who takes on ultimate responsibility for the initiation, management, financing (or arranging the financing) of a clinical trial. SOP Standard Operating Procedure. Written instructions and records of procedures agreed and adopted as standard practice. TM TMF Trial Manager Trial Master File
11 SOP number: NWORTH 3.07 Page 11 of 11 File kept at NWORTH for each trial containing essential documents for that trial, as defined for CTIMP in section 8 of ICH GCP) TMG TSC Trial Management Group Trial Steering Committee 8. References 1. Fellows, T., ICH Harminised Tripartite Guideline for Good Clinical Practice. GCP Training. 2004, Marlow, Bucks: Institute of Clinical Reserach. 2. University of Sheffield, Standard Operating Procedure ( SOP ) for Universitysponsored Clinical Trials of Investigational Medicinal Products ( IMP-Trials ): Monitoring of University-Sponsored Clinical Trials of Investigational Medicinal Products (IMP-Trials). 2006, University of Sheffield: Sheffield. 3. National Institute of Allergy and Infectious Diseases, Clinical Trial Monitoring SOP. 2007, National Institute of Allergy and Infectious Diseases. 4. The European Parliament and the Council of the European Union, Directive 2001/20/EC of the European Parliament and of the Council of 4 April Official Journal of European Union, Article 2(Definitions): p. L121/36- L121/ ICH E6 (R1) Guideline to good clinical practice Referenced SOPs NWORTH Training SOP 2.01 NWORTH Protocol development SOP 3.02 NWORTH Trial initiation and Site set up SOP 3.03 NWORTH Trial supplies/labelling SOP 3.08 NWORTH NHS Ethical and Research & Development Approval SOP 4.01 NWORTH MHRA approval SOP 4.02 NWORTH Safety monitoring including Pharmacovigilance SOP 4.03 NWORTH Arranging sponsorship, contracts/agreements and indemnity SOP Appendices None
Standard Operating Procedure for Archiving
Standard Operating Procedure for Archiving SOP name: NWORTH07/19 archiving Version 2 Authorship Team: Angela Gliddon & Rhiannon Whitaker Meeting date reviewed 16 th April 2008 Designated NWORTH member
More informationDate: 2 nd June 2010 Version: 3 Page 1 of 16 AND LABELLING (NWORTH 3.08) Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10
Page 1 of 16 STANDARD OPERATING PROCEDURE FOR TRIAL SUPPLIES AND LABELLING (NWORTH 3.08) Approvals Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10 Quality Assurance Officer Name: D.
More informationTrial oversight SOP for HEY-sponsored CTIMPs
R&D Department Trial oversight SOP for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored in a retrieval system
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationIMP Management and Accountability
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationSponsorship of Clinical Research Studies
Sponsorship of Clinical Research Studies Category: Summary: Equality Impact Assessment undertaken: Policy The UK Policy Framework for Health and Social Care 2017 (UKPF) and The Medicines for Human Use
More informationDevelopment Safety Update Report Guidance
Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational
More informationInvestigational Medicinal Product (IMP) Management Standard Operating Procedure
Reference Number: UHB 040 Version Number: 3 Date of Next Review: 26 Apr 2019 Previous Trust/LHB Reference Number: T 363 Standard Operating Procedure Introduction and Aim This procedure is written to support
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationInspections: an academic perspective
Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk
More informationManagement and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility
Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility Document Detail Document type Standard Operating Procedure CRF-STU-SOP-1: Management and Accountability
More informationTrial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products
1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible
More informationSTANDARD OPERATING PROCEDURE SOP 320. Developing a Research Protocol
STANDARD OPERATING PROCEDURE SOP 320 Developing a Research Protocol Version 2.1 Version date 26.03.2017 Effective date 26.03.2017 Number of pages 14 Review date April 2019 Author NNUH UEA Joint Research
More informationRecording, Managing and Reporting Adverse Events in the UK
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationGood Clinical Practice
Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete
More informationTrial Protocol. Version 1.2. Effective date: 18 May Dr Sarah Duggan, CTU Manager. V May 2010 Update web links.
Trial Version 1.2 Effective date: 18 May 2010 Reviewed by: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Reason for change V1.2 18 May 2010 Update
More informationAuthor Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document
SOP Title: Investigator s Brochure Content, Design, Amendments, Filing & Distribution Author: Clinical Research and Development Office (CRDO) Author Signature: Date: 10 October 2017 The author is signing
More informationQuality Assurance in Clinical Trials
Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:
More informationEuropean Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells)
European Academy of Hospital Pharmacy Biotechnology Educational Summit Clinical trials David Gerrett (Acknowledgment Mark Howells) Objectives Have an appreciation and overview of clinical trials Understand
More informationMRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council
MRC Clinical Trials Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 Medical Research Council MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 MRC GUIDELINES FOR
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Archiving and the Destruction of Records SOP-RES-028 Version Number 2 Issue Date 08 th Dec 2015 Effective Date 22 nd January 2016 Review Date 22 nd January
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Trial Master File & Investigator Site File SOP number: TM 001 SOP category: Trial Management Version number: 03 Version
More informationSTANDARD OPERATING PROCEDURE SOP 310
STANDARD OPERATING PROCEDURE SOP 310 DEVELOPMENT OF PARTICIPANT INFORMATION SHEET AND INFORMED CONSENT FORM Version 1.3 Version date 28.03.2017 Effective date 28.03.2017 Number of pages 8 Review date April
More informationClinical Trials application process, legislation & guidelines
Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission
More informationMarie-Claire Good, RG and GCP Manager James Rickard, Deputy Chief Pharmacist Technical Services Cheryl Lawrence, Senior Research Pharmacist
Standard Operating Procedures (SOP) for: IMP Management BH/QMUL Sponsored CTIMPs SOP Number: 42a Version Number: 3.0 Effective Date: 14 th August 2017 Review Date: 14 th August 2019 Author: Reviewer: Reviewer:
More informationECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies
ECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies SOP number: ECTU TM 17 Signature Date Authored by: Holly Ennis, Trial Manager 6 th Sept 2017 Reviewed by: Laura Forsyth, Trial Manager
More informationStephanie Gentilin, CCRA
Elements of Clinical Trial Quality Assurance Stephanie Gentilin, CCRA Regulatory Coordinator SCTR SUCCESS Center QA Monitor NIDA Monitor s Responsibilities ICH E6 Section 5.18 Overall Purpose of Monitoring
More informationEssential Healthcare Research Governance Processes. Cindy Cooper, Lindsay Unwin and Judith Cohen, UoS
Essential Healthcare Research Governance Processes Cindy Cooper, Lindsay Unwin and Judith Cohen, UoS Aims Overview of governance processes including recent changes to remit Reminder of HoD and PI responsibilities
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationSINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP)
SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP) Date of Implementation: 1 August 1998 Date of First Revision: 1 October 1999 Printed in July 1998, August 1998 and September 1999. Adapted from the
More informationetmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector
etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector Agenda EU Legislation and Guidance News/Updates relating to TMF Structure and Content of e/tmf Inspecting etmfs
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More informationStandard Operating Procedure: Obtaining Informed Consent from Competent Adults for Research Studies. SOP Number: UoA-NHSG-SOP-010 Version No: 2
Standard Operating Procedure: Obtaining Informed Consent from Competent Adults for Research Studies SOP Number: UoA-NHSG-SOP-010 Version No: 2 Author: Date: 27 th March 2015 (Carole Edwards, Lead Research
More informationWorkstream 6: Pharmacovigilance
Workstream 6: Pharmacovigilance 1.0 Introduction... 2 1.1 Background... 2 1.2 Definitions... 3 2.0 Definition of Sponsor for Pharmacovigilance... 4 3.0 General Considerations: Risk Adapted Approaches to
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical
More informationR&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:
Research as a Participating site STANDARD OPERATING PROCEDURE FOR OVERSIGHT SOP No: P08/PF2 V2 Effective Date: 31 st July 2013 Supersedes: P08/PF2 Revision Date: 31 st March 2014 Author: Position: Approved
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More informationAudit Program Background Definition Management Example Content Risk assessment approach
AUDIT PROGRAM Audit Program Background Definition Management Example Content System audits vs study audits Risk assessment approach ICH-GCP E6 new content Management Example 2 Background - Definition There
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationPROTOCOL DRAFTING GUIDE
MUHC Research Ethics Board (Neurosciences & Psychiatry) Comité d éthique de la recherche du MUHC (Neurosciences & psychiatrie) PROTOCOL DRAFTING GUIDE LIST OF ITEMS TO BE INCLUDED IN A PROTOCL FOR RESEARCH
More informationConfirming Research Study Capacity and Capability
Title: Outcome Statement: Written By: Confirming Research Study Capacity and Capability Researchers will be informed about the procedures and requirements for obtaining permission to conduct a research
More informationCVM Guidelines and Guidance Documents
CVM Guidelines and Guidance Documents No. 85 (VICH GL9) Good Clinical Practice U.S. Department of Health and Human Services Food and Drug Administration Center of Veterinary Medicine May 9, 2001 PDF version
More informationMarie-Claire Rickard, RG and GCP Manager Cheryl Lawrence, Senior Research Pharmacist Damien Kelly, Barts Pharmacy Site and Clinical Trials Lead
Standard Operating Procedures (SOP) for: Pharmacy Involvement in Hosted Studies SOP Number: 42b Version Number: 2.0 Effective Date: 23 rd November 2015 Review Date: 2 nd November 2017 Author: Reviewer:
More informationGood Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations
Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland Question 1: What laws or regulations apply to an application for conducting a clinical
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Training and Development SOP-QMS-007 Version Number 2 Issue Date 15 Apr 2016 Effective Date 26 May 2016 Review Date 26 May 2018 Author(s) Reviewer(s)
More informationSTUDY CLOSURE AND ARCHIVING
STUDY CLOSURE AND ARCHIVING DOCUMENT NO.: CR009 v2.0 AUTHOR: Lynn Smith ISSUE DATE: 15 August 2016 EFFECTIVE DATE: 29 August 2016 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Creation & Maintenance of an Investigator Brochure SOP Number: 34 Version Number: 1.0 Supercedes: N/A Effective date: August
More informationReflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples
1 2 3 26 August 2010 EMA/INS/GCP/532137/2010 GCP Inspectors Working Group 4 5 6 Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples Draft Adoption
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationGood Clinical Practice
Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie
More informationII. Clinical Trial Regulation Challenges for National Competent Authorities Perspective of BfArM Thomas Sudhop, MD
II. Clinical Trial Regulation Challenges for National Competent Authorities Perspective of BfArM Thomas Sudhop, MD Selected Topics Definitions Communication & Interaction Phase I Clinical Trials Safety
More informationClinical trials from CRA s point of view
Clinical trials from CRA s point of view Dr Jacek S Gregorczyk MPharmS, PhD Clinical Research Associate (CRA) at MDS Pharma Services UK office - a global CRO REGULATION of CLINICAL TRIALS World Medical
More informationSOP04: Standard Operating Procedure for Trial Supplies and Labelling
SOP04: Standard Operating Procedure for Trial Supplies and Labelling Authorship Team: Anne Seagrove & Mair Roberts Joint SOP Group on Trial Administration (viz Angela Evans, Sarah Gaze, Hayley Hutchings,
More informationResearch Governance Policy and Procedure
Research Governance Policy and Procedure Version: 5 Name of originator/author: Name of executive lead: Date ratified: Review date: APPLICABLE TO: All staff. EXECUTIVE SUMMARY Dr Lisa Austin- University
More informationThis is a controlled document. The master document is posted on the JREO website and any print-off will be classed as uncontrolled.
Standard Operating Procedure (SOP) Investigator Preparation of Annual Developmental Safety and Update Report (DSUR) and its review and submission by the Sponsor SOP ID number: JREOSOP0008 Effective Date:
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationMEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155
MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part
More informationGuideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File
Guideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File Turkish Medicines and Medical Devices Agency 16.02.2015 CHAPTER I... 2 1.1. Introduction... 2 CHAPTER II...
More informationHuman Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance
Human Research Audit Program Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Monday, September 11, 2017 Objectives 1. Understand the purpose of the audit program 2. Identify
More informationGUIDANCE NOTES FOR MANUFACTURERS OF CLASS I MEDICAL DEVICES
MDEG - 2007-12 - II-3.3 MSOGClassIGuidance_Final GUIDANCE NOTES FOR MANUFACTURERS OF CLASS I MEDICAL DEVICES Foreword These guidance notes do not aim to be a definite interpretation of National Laws and/or
More informationMulti-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18
Multi-Site Coordination Process Drafted by: Ester Dimayuga Page 1 of 18 MULTI-SITE COORDIATIO (MSC) REGULATOR PROCESS CTO-Regulatory notifies MSC of trial with UMCC as coordinating center MSC prepares
More informationStandard Operating Procedure for Statistical Reports
Reports_V01.doc Page 1 of 6 Standard Operating Procedure for Statistical Reports SOP ID Number: Effective Date: 22/01/2010 Version Number & Date of Authorisation: V01,15/01/2010 Review Date: 22/01/2012
More informationSupply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017
Supply of aseptically - prepared doses of IMPs across legal boundaries Edition 1 December 2017 Endorsed and supported by: NHS Pharmaceutical Quality Assurance Committee 2017 with National Pharmacy Clinical
More informationAgenzia Italiana del Farmaco
Agenzia Italiana del Farmaco The Italian Legislation and the work of the Italian Medicines Agency (AIFA) in the field of ethics of Clinical Trials Umberto Filibeck AIFA Head of GCP Inspectorate and GCP
More informationPrecision-Panc Master Protocol: Personalising treatment for pancreatic cancer.
Precision-Panc Master Protocol: Personalising treatment for pancreatic cancer. Initiation Slides (Version 1 Draft 2 : 30 th October 2017) Sponsor: NHS Greater Glasgow and Clyde Chief Investigators: Dr
More informationCombined trial of an investigational medicinal product and an investigational medical device
Welcome to the Integrated Research Application System IRAS Project Filter The integrated dataset required for your project will be created from the answers you give to the following questions. The system
More informationClinical Trials Management for Molecular Diagnostics. April 2016
Clinical Trials Management for Molecular Diagnostics April 2016 Clinical Operations Responsibilities Accrue samples that have proper informed consent for use Retrospective cohorts Remnant samples Prospective
More informationIRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010
IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationCompetence in Clinical Trials the Regulators Perspective.. (Jennifer Martin Senior GCP Inspector, 9 June 2014)
Competence in Clinical Trials the Regulators Perspective. (Jennifer Martin Senior GCP Inspector, 9 June 2014) Requirements Statutory Instrument 2004/1031 (as amended) Regulation 28(2): The sponsor (and
More informationGCP Convergence Improves Transportability of Medical Device Clinical Data
GCP Convergence Improves Transportability of Medical Device Clinical Data By Harmonization-by-Doing Working Group 4 The safety, performance and effectiveness of medical devices are often evaluated by well-controlled
More informationREQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE:
Annex 1: Clinical trial Application Form REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE
More informationClinical Research & ICH GCP E6(R2) (Basic / Refresher Training):
Clinical Research & ICH GCP E6(R2) (Basic / Refresher Training): Principles of GCP, Investigator Responsibilities, Essential Documents v3 01-Feb-2017 Objectives To provide refresher training on ICH GCP
More information5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)
5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples
More informationQuality Assurance in Clinical Trials Introduction
Quality Assurance in Clinical Trials Introduction Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 2012 1 Delphine TEPPE-CROITROU - Catherine CORNU (Hospices Civils de Lyon)
More informationReview PROCESS, decision making PROCESS and communication BY
Review PROCESS, decision making PROCESS and communication BY ethics committee Dr. Reneega Gangadhar, Professor & Head Department of Pharmacology Govt. Medical college Trivandrum Outline Review process
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationHuman Samples in Research
Human Samples in Research Import and Export of Human Tissue Document Identifier HTA-06-SOP-Import and Export AUTHOR APPROVER EFFECTIVE DATE: Name and role Signature and date Name and role Signature and
More informationISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual
The StAmP Trial: A Proof of Principle, double blind, Randomised Placebo-Controlled, Multi Centre Trial of Statins to Ameliorate Early Onset Pre-eclampsia. ISRCTN: 23410175 EudraCT Number: 2009-012968-13
More informationQuality Site Visit Report FGK Clinical Research (FGK) GmbH, Munich Germany. Audit No. CT6018. Date of Audit: 3rd to 5th May 2017
Quality Site Visit Report FGK Clinical Research (FGK) GmbH, Munich Germany Head Office Address FGK Clinical Research GmbH Heimeranstrasse 35, 80339 Munich, Germany Research Centre Address FGK Clinical
More informationICH/GCP Guidelines Self-Evaluation Questionnaire
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 74 82 (1997) ICH/GCP Guidelines Self-Evaluation Questionnaire The questionnaire below has been designed as a diverting, internal training tool by a group of employees
More informationCompetent federal higher authority ("Bundesoberbehörde- BOB")
Nutrition/InterventionaI - GERMANY Competent authority Contact Details Contact Name 1 Competent federal higher authority ("Bundesoberbehörde- BOB") Contact Name 2 Federal Institute for Drugs and Medical
More informationGuide to Clinical Trial Applications
Guide to Clinical Trial Applications AUT-G0001-11 29 MAY 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS 3 1
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines
More informationResearch Governance Policy
Research Governance Policy Version: Status: Title of originator/author: Name of responsible director: Developed/revised by group/committee and Date: Approved by group/committee and Date: Effective date
More informationMEDICINES CONTROL COUNCIL
Clinical Trial Application Form MEDICINES CONTROL COUNCIL APPLICATION TO CONDUCT A CLINICAL TRIAL Study title Protocol No. Version No. Study Drug MCC Ref. no. (if applicable) MCC Ref number(s) of comparator
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationDue diligence in the European medical devices industry
Due diligence in the European medical devices industry Alison Dennis, Reed Smith LLP www.practicallaw.com/0-205-5707 As the medical devices industry is highly regulated, determining a target company's
More informationHow to Set Up and Manage Quality Control and Quality Assurance
How to Set Up and Manage Quality Control and Quality Assurance Myriam Visschedijk 1, *, Rik Hendriks 2 and Katrien Nuyts 3 1 TNO Quality of Life, The Netherlands 2 Johnson & Johnson Pharmaceutical Research
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Audits and Inspections SOP-QMS-004 Version Number 4 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s)
More informationData Collection Tools Functions, Indicators & Sub-Indicators
Data Collection Tools 27- Functions, Indicators & A. National regulatory system Indicator RS1: Legal framework for establishment of a regulatory system, mandate and enforcement power for each function
More informationNOTICE OF SUBSTANTIAL AMENDMENT
NOTICE OF SUBSTANTIAL AMENDMENT For use in the case of all research other than clinical trials of investigational medicinal products (CTIMPs). For substantial amendments to CTIMPs, please use the EU-approved
More informationPHARMACY, MEDICINES & POISONS BOARD
PHARMACY, MEDICINES & POISONS BOARD PHARMACY GUIDELINES FOR INVESTIGATIONAL DRUGS A. Purpose These guidelines are principally derived and adapted from guidelines from various sources within the SADC region.
More informationFDA Sponsor and Investigator Responsibility Checklist
FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator
More information